Not independent
Tenure on this board
4.4 yrs
Meeting calendar
NVCT · Annual meeting · Thursday, June 11, 2026
Nuvectis Pharma Inc
1 nominee · 2 ballot items.
Elect one Class I director (Ron Bentsur) for a three-year term; Ratify the appointment of Kesselman & Kesselman as the company’s independent registered public accounting firm for the year ending December 31, 2026.
Market cap
$485M
1Y TSR
+134.4%
Board grade
B+
Record date
Apr 13, 2026
Filing
DEF 14A
Meeting concluded · Jun 11, 2026
Follow how the vote landed and what changed on Nuvectis Pharma Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Class I Director — Ron Bentsur
ManagementBoard: FORRe-election of Ron Bentsur as a Class I director to serve a three-year term expiring at the 2029 annual meeting.
- 2
Ratification of Appointment of Kesselman & Kesselman as Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the selection of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as the Company's independent registered public accounting firm for the year ending December 31, 2026.
Director elections
Nominees on the ballot1
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 659,879 | $5M |
| 2 | IRIDIAN ASSET MANAGEMENT LLC/CT | 2.5% | 651,757 | $5M |
| 3 | BlackRock, Inc. | 2.0% | 519,502 | $4M |
| 4 | Occam Crest Management LP | 1.5% | 407,147 | $3M |
| 5 | BALDWIN WEALTH PARTNERS LLC/MA | 1.4% | 378,625 | $3M |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.2% | 326,133 | $3M |
| 7 | BlackRock, Inc. | 0.7% | 174,448 | $1M |
| 8 | STATE STREET CORP | 0.6% | 166,516 | $1M |
| 9 | VANGUARD FIDUCIARY TRUST CO | 0.4% | 114,842 | $888K |
| 10 | NORTHERN TRUST CORP | 0.4% | 113,542 | $878K |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Nuvectis Pharma Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$724M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.8B
Reference
Frequently asked questions
- When is the Nuvectis Pharma Inc 2026 annual meeting?
- Nuvectis Pharma Inc (NVCT) holds its 2026 annual shareholder meeting on Thursday, June 11, 2026.
- What is the record date for the Nuvectis Pharma Inc 2026 meeting?
- The record date for the Nuvectis Pharma Inc 2026 meeting is Monday, April 13, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Nuvectis Pharma Inc's 2026 meeting?
- The board is presenting 1 director nominee at the Nuvectis Pharma Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Nuvectis Pharma Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Nuvectis Pharma Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.